Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyungpook National University; Kyungpook National University Hospital
• Treatments: Nafamostat

Criteria

Inclusion Criteria:

• Patients who were admitted to the intensive care unit and required CRRT

1. active bleeding such as gastrointestinal bleeding and intracranial hemorrhage,

2. activated partial thromboplastin time > 60 s,

3. prothrombin time-international normalized ratio > 2.0,

4. thrombocytopenia (<100,000/µL), and

5. surgery within 48 h before CRRT.

Exclusion Criteria:

• Pregnant or possibly pregnant women

• Patients who were allergic to nafamostat mesilate

• Patients who were hypercoagulable